23andme glp 1 As a medical school professor, I get asked why GLP-1 drugs work miracles for some and barely budge for others. A new Nature paper from gives part of the answer: your 23andMe's New GLP-1 Service: Exploring

Some clinics and patients post anecdotal sermorelin before and after face comparisons, especially when combined with aesthetic treatments

Competitive Position Eli Lilly Market Cap: ~$885-930B 2025 Rev Growth: +40-50% Forward P/E: ~31 Positioning: Market leader, oral GLP-1 coming Novo Nordisk Market Cap: ~$204-215B 2025 Rev Growth: +30% Forward P/E: ~12 Positioning: Struggling with competition, stock down 60% from peak Pfizer Market Cap: ~$160B 2025 Rev Growth: Declining Forward P/E: ~12 Positioning: Lost Metsera bid to competition Key Advantages: Tirzepatide (Mounjaro/Zepbound) consistently outperforms Novo's semaglutide (Ozempic/Wegovy) in head-to-head trials First-mover advantage with oral GLP-1 (orforglipron) Manufacturing scale-up: $12.5B+ invested in new facilities (Virginia, Texas, Puerto Rico) Direct-to-consumer platform (LillyDirect) creating pricing flexibility Valuation & Price Targets Current Price: ~$990 Market Cap: ~$885-930B Valuation Framework 2025 Est

As the regional director for clinical nutrition and weight management

Accessed June 19, 2024

For a complete step-by-step guide, visit our peptide reconstitution guide